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Abstract
Background: Currently there are few studies characterising the nature and aetiology of human schistosome-related
inflammatory processes. The aim of this study was to determine the relationship between Chitinase 3-like 1 (CHI3L1), also
known as YKL-40, a molecule associated with inflammatory processes, and schistosome infection, morbidity and systemic
cytokine levels.
Methods: Serological levels of CHI3L1 and a panel of cytokines (IFN-y, IL-4/5/6/9/10/13 and 17) were measured in two
Zimbabwean populations resident in a high and low schistosome infection area. CHI3L1 levels were related to schistosome
infection, haematuria status and cytokine levels after allowing for confounding variables. The effect of antihelminthic
treatment with praziquantel on CHI3L1 levels was determined in 246 participants 6 weeks post-treatment.
Results: CHI3L1 levels increased with age in both areas but were significantly higher in the high infection areas compared to
the low infection area. CHI3L1 levels were also higher in infected compared to uninfected individuals with this difference
being significant in the youngest age group. Curative antihelminthic treatment resulted in a significant decrease in CHI3L1
levels. Of the cytokines, only IL-10 and IL-17 had a significant association with CHI3L1 levels, and this association was
negative.
Conclusions: Serum CHI3L1 levels differ between infected and uninfected people before and after antihelminthic treatment.
The greatest difference occurs in the youngest age group, in keeping with the period when schistosome-related
pathological processes are initiated. Following from previous studies in non-infectious diseases showing that CHI3L1 is a
biomarker for the inflammatory process, this study suggests that the potential for CHI3L1 as a biomarker for schistosome-
related pathology should be explored further.
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Introduction
Urogenital schistosomiasis, caused by the blood fluke Schistosoma
haematobium, is one of the world’s most prevalent human parasitic
diseases. Morbidity includes anaemia, malnutrition, impaired
memory cognition and physical growth [1], and immune-
mediated pathology in the urogenital tract, the kidneys and
ureters [2]. Immunopathology commences with the laying of eggs
in the blood vessels at the site of infection where they cause
damage to the bladder walls and genital tissues in the form of
lesions in blood vessels and tissues leading to the common
symptom of haematuria. Antigens secreted by these eggs induce a
Th2 response, involving secretion of interleukin-4 (IL-4), IL-5 and
IL-13 [3,4] and the eventual development of granulomas [5,6].
Resolution of the granuloma involves deposition of collagen and
extra-cellular matrix components, which are the source of fibrosis
[5,7,8]. In young children infected with S. haematobium egg
deposition is associated with more acute inflammatory symptoms,
visible haematuria, anaemia and a high egg output in what is
known as the active stage of disease [7]. This progresses with age
to an inactive stage characterised by a drop in urine egg counts as
fewer eggs are excreted but more become trapped and calcified in
tissues. It is during the inactive stage of disease that signs of
extensive and sometimes irreversible fibrotic pathology can be
detected [7], while in those still acquiring active infection most of
the schistosomiasis associated morbidity is reversible upon
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antihelminthic treatment [9]. Schistosome control programmes
aim to reduce morbidity by reducing infection intensity and their
success is monitored through egg counts [10,11]. However, egg
counts as a measure of disease burden can be misleading as the
relationship between morbidity and infection intensity can be non
linear, for example there can be a discrepancy between an
individual with a high worm burden displaying less pathology than
an individual with a low worm burden [10,12]. Haematuria, has
been used in numerous studies as both a marker for infection and
onset of pathology [10], it is particularly effective in detecting
infection in younger age groups. However, haematuria can have a
low sensitivity rate [13]. Ultrasonography provides a more reliable
method for assessing pathology in schistosomiasis infection [10]
but operational logistics, such as the requirement for trained
personnel and a consistent power source, make it an unsuitable
tool for large scale or rural field studies [14]. In addition, despite its
effectiveness in detecting late stage disease, ultrasound can fail to
detect the earlier pathological changes associated with infection
mediated inflammation [15]. Identification of biomarkers that can
detect early pathological changes related to schistosomiasis
infection, and changes associated with treatment, would provide
an invaluable tool in monitoring schistosome control programmes
[11].
Chitinase-like proteins are a characteristic feature of multiple
helminth infection models [16,17]. Chitinase 3-like 1 (CHI3L1),
also known as human cartilage glycoprotein 39 (HCgp-39), and
YKL-40, is a human chitinase-like chitin-binding lectin with no
chitinase enzymatic activity [16,17]. It is expressed by numerous
cell types and has been associated with collagen and extra-cellular
matrix formation [18] as well as with a wide range of diseases
characterised by inflammation and tissue remodelling including
asthma, arthritis, numerous cancers and liver fibrosis [19,20,21].
Recently CHI3L1 has also been linked to schistosome related
hepatic fibrosis with S. japonicum infection [22]. In order to evaluate
the potential of CHI3L1 as a pathology marker in urogenital
schistosomiasis, and to investigate the nature of pathological
changes associated with infection, the association of serum
CHI3L1 levels with schistosome infection status, prevalence and
history of exposure to infection was determined in individuals from
three villages in rural Zimbabwe with differing levels of S.
haematobium endemicity. Comparing villages of different endemicity
allows a comparative approach separating the effects of history of
schistosome infection from current infection levels, both factors
that can potentially influence CHI3L1 levels [23]. The effect of
curative antihelminthic treatment on CHI3L1 was determined in a
post-treatment follow-up focussed on the village with highest
endemicity. In addition we assessed the protein’s relationship with
a panel of systemic cytokines encompassing the range of Th1, Th2,
Th17 and T-regulatory responses associated with schistosome
infection and pathology (see [24,25] for review), thus allowing
CHI3L1 levels to be related to the immune environment in the
host relative to their immune phenotype.
Materials and Methods
Ethical Statement
The study was conducted in the Mashonaland East Province of
Zimbabwe where S. haematobium is endemic. Ethical approval was
received from the University of Zimbabwe’s Ethics Review Board
(UZERB) and the Medical Research Council of Zimbabwe
(MRCZ), and permission to conduct the study was obtained from
the Provincial Medical Director. The study design, aims and
procedures were explained in the local language, Shona, prior to
enrolment. Written consent was obtained from participants or
their guardians prior to taking part in the study.
Study area and population
The study was conducted within schools, recruiting school
children and community members from three villages and details
are described elsewhere [26]. Of the three villages Magaya
(17u379210S 31u549360E) and Chipinda (17u419460S 31u569030E)
are considered high infection areas (HIA) for schistosome
infection, while Chitate (17u399450S 31u539210E) is a low infection
area (LIA) as defined by the World Health Organization (WHO)
[11]. The area has a low prevalence of soil transmitted helminths
[27], and the residents are subsistence farmers with frequent
contact with infected water for purposes of bathing, washing and
collecting water. Plasmodium falciparum is the predominant species of
malaria in Zimbabwe, and in this region malaria transmission is
largely unstable in nature, classified as low and sporadic [28,29],
giving a low prevalence of co-infection between schistosome
infection and Plasmodium infection in the study population.
Sample collection
From each participant a stool and urine specimen was collected
on three consecutive days and examined microscopically. Urine
samples were examined for S. haematobium infection and stool
samples were examined for S. mansoni and soil transmitted
helminths using standard techniques [30,31]. Urine samples from
children were examined for visible haematuria and designated
positive when haematuria was observed or negative when no
haematuria was observed. Macrohaematuria was confirmed on a
different urine sample by dipstick (Uripath, Plasmatec, UK). 5 ml
venous blood was collected and processed using routine methods
to collect serum which was frozen at 220uC prior to freighting to
Edinburgh for serological assays. Following parasitology sample
collection, participants were offered treatment with the anti-
helminthic drug praziquantel at the recommended dose of 40 mg/
kg of body weight and treatment efficacy was checked 6 weeks
later during follow-up parasitology and serological surveys.
Author Summary
Over 100 million people, mainly living in sub-Saharan
Africa, are infected with the blood fluke Schistosoma
haematobium. Morbidity includes anaemia, malnutrition,
impaired cognition and physical growth as well as
pathology of the urogenital tract. Urogenital morbidity is
initiated by eggs laid at the site of infection causing
mechanical damage and leading to haematuria, or blood
in the urine. Eggs also secrete antigens, triggering a
protective granuloma to form around the eggs which can
lead to fibrosis and organ failure. Currently there are few
non invasive markers of schistosome-related pathology
hampering diagnosis and evaluation of control pro-
grammes. Chitinase 3-like 1 (CHI3L1) has been associated
with several inflammatory disorders involving tissue
remodelling. In this study we assessed the levels of CHI3L1
in a group of individuals from a schistosomiasis endemic
area in Zimbabwe. We showed that CHI3L1 is elevated in
schistosomiasis infected individuals over uninfected indi-
viduals, with the strongest association seen in the
youngest age group who have a shorter history of
schistosome infection. Treating individuals with a drug
that eliminates the adult worm leads to a decrease in
CHI3L1 in infected individuals. These results suggest that
the potential for CHI3L1 as a biomarker for schistosome-
related pathology should be explored further in different
human populations.
Chitinase 3-Like 1 in Human Schistosomiasis
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Treatment of the three communities was staggered by 6 weeks for
the purpose of an untreated control group except in the case of
heavily infected people as defined by the WHO [11].
Inclusion/Exclusion Criteria
In order to be included in this study participants had to meet the
following criteria: 1) be lifelong residents of the study area to allow
age to be used as a proxy for history of exposure to schistosome
infection, 2) have provided at least two urine and two stool samples
on consecutive days for parasite detection, 3) have provided a
blood sample for serological assays, 4) not have previously received
antihelminthic treatment, 5) be negative for co-infections (malaria,
intestinal helminths, S. mansoni and HIV). From an initial number
of 2000 individuals, a total of 859 individuals 2–86 years old, 642
from the HIA and 217 from the LIA, met these criteria. The post-
treatment study focused on the HIA where there was a higher
prevalence of infection. To be included in the post-treatment study
individuals had to meet the criteria above and be confirmed egg
negative 6 weeks post-treatment or remain untreated for the
control group. 246 participants (110 treated and 136 untreated)
fulfilled these criteria and formed the follow-up cohort.
Serological assays
Serum levels of CHI3L1 were quantified using an ELISA kit
from R&D Systems (Cat DY2599, Minneapolis, USA), following
the manufacturer’s instructions. Systemic levels of IL-10, IL-17,
IFN-c, IL-13, IL-4, IL-5 and IL-6 were measured by ELISA as
previously described [32,33]. All serological assays were performed
in duplicate with a positive control on each plate.
Statistical analysis
Statistical analyses were conducted using the statistical package
SPSS version 14.0. To describe the age profiles of schistosome
infection and CHI3L1 protein, an analysis of variance (ANOVA)
was performed using infection intensity (eggs/10 ml urine) and
CHI3L1 levels (ng/ml) log transformed (log10(x+1)). The inde-
pendent variables were age categorised into 6 groups as shown in
Table 1. Following these analyses, age was re-categorised to reflect
the changing dynamics of rising (2–10 years), peaking (11–20
years) and declining (21+years) infection. Using these age groups
the effect of schistosome infection (infection intensity (log
transformed (log10(x+1)) or infection status (infected vs. uninfect-
ed)) and age group on CHI3L1 protein was determined by
ANOVA after allowing for the effects of sex and village of
residence through sequential sums of squares. The interaction
between infection and age groups was also tested. To determine if
CHI3L1 levels were higher in children with visible haematuria, the
positive cases were matched with age, sex and infection intensity
matched controls and the data analysed by t-test.
The effect of antihelminthic treatment on CHI3L1 levels was
analysed using a repeated measures ANOVA followed by posthoc
analysis within each age group. In order to relate systemic cytokine
to CHI3L1 levels the number of cytokine variables was reduced
using factor analysis. Individual cytokine responses (square-root
transformed) with no rotation were used to extract uncorrelated
principal components (PC) accounting for a significant proportion
of variance in the data (eigenvalues greater than 1) and with a
factor loading of .0.5 or ,0.5 for one or more of the original
cytokine variables. The PCs arising from this procedure were then
used in a partial correlation (controlling for age group, sex and
residential area) relating the PCs to CHI3L1 levels with the 2-
tailed p value from the correlation being reported. P values in all
statistical tests were considered significant if p#0.05.
Results
Levels of schistosome infection and CHI3L1 vary with
residential area and age
After accounting for sex schistosome infection intensity and
prevalence were significantly higher in the HIA (mean infection
intensity = 27 eggs/10 ml urine, prevalence= 40%) compared to
the LIA (prevalence = 11.1%; mean infection intensity = 2.7 eggs/
10 ml urine) (F1,858 = 55.158, p,0.001). The schistosome-age
profiles differed in the two residential areas resulting in a
significant age group*residential area effect (F5,858 = 2.446,
p = 0.033) giving rise to the ‘peak shift’ [34]; whereby the infection
peak occurred at a higher intensity and at an earlier age in the
HIA compared to the LIA (as shown in Figure 1A). Overall, after
accounting for sex, CHI3L1 levels were also significantly higher in
the HIA (mean, 59.9 ng/ml; SEM, 2.03) compared to the LIA
(mean, 49.1; SEM 5.15), (F1,858 = 59.722, p,0.001). In both
villages CHI3L1 levels rose significantly with age group as shown
in Figure 1B and Table 2, but no peak shift occurred in CHI3L1
levels.
CHI3L1 levels are elevated in infected individuals, and in
haematuric cases
CHI3L1 levels were higher in infected vs. uninfected people,
after allowing for the confounding effects of age and residential
area, with this difference being significant in the youngest age
group (Table 2, Figure 2). Interestingly, infection intensity, when
analysed in the same model, did not significantly affect CHI3L1
Table 1. Description of study population.
High Infection Area Low Infection Area
Age group (years) Infection Range (N) M (N) F (N) Infection Range (N) M (N) F (N)
2–10 0–865 (273) 136 137 0–28 (74) 37 37
11–15 0–743 (202) 97 105 0–165 (59) 29 30
16–20 0–720 (43) 20 23 0–76 (18) 6 12
21–30 0–52 (21) 1 20 0 (23) 3 20
31–40 0–21 (23) 2 21 0 (14) 14 0
41+ 0–14 (80) 9 71 0–8 (29) 5 24
Total 0–865 (642) 265 377 0–165 (217) 80 137
Note. Infection Range (eggs/10 ml urine) and sample sizes, according to age group. Abbreviations: N, sample size; M, male; F, female.
doi:10.1371/journal.pntd.0001898.t001
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levels (F1,858 = 2.016, p = 0.156). The pattern was maintained,
though was not significant, in the older age groups. Comparison of
CHI3L1 levels in 34 children aged 6–16 years showed a higher
level of CHI3L1 in the children with visible haematuria compared
to the infection matched children who were not presenting with
haematuria (t =21.1662; df = 32; p = 0.053) as shown in Figure 3.
Neither the mean age nor the mean infection intensity was
significantly different between these 2 groups (t = 0.067; df = 32;
p = 0.947 for age, and t =20.595; df = 32; p = 0.556 for S.
haematobium infection intensity).
Praziquantel treatment is associated with a decrease in
CHI3L1 level
To address the question of whether CHI3L1 is associated with
infection, 246 participants from the HIA were followed up for 6
weeks post-treatment. All treated individuals included in this study
were negative for infection 6 weeks post-treatment, as determined
by egg counts. In treated people, mean CHI3L1 levels declined
significantly from 63.7 ng/ml (SEM, 3.06) pre-treatment to
48.2 ng/ml (SEM, 4.75) post-treatment (p,0.001). In contrast,
there was no significant change in mean CHI3L1 levels in the
untreated group (47.3 ng/ml; SEM=2.18 at baseline, and
52.3 ng/ml; SEM=3.52 6 weeks later, p = 0.855). Partitioning
the cohort by age group showed that the post-treatment decline
was significant in the youngest age groups (2–10 year olds:
F53 = 23.942, p,0.001; 11–20 year olds F51, = 4.161, p = 0.047),
while there was no significant change in the oldest age group
(F6 = 3.25, p = 0.146) (Figure 4).
CHI3L1 has a negative relationship with IL-10 and IL-17
The data reduction procedure conducted on the 8 cytokines
returned 4 main PCs summarised in Table 3. PC1, accounting for
the largest variation in cytokine levels, was composed of Th2-type
cytokines (IL-4, IL-5 and IL-9). PC2 was composed of T-
regulatory (IL-10) and Th17 (IL-17A) type cytokines. PC3 was
composed of IL-13, and PC4 was a pro-inflammatory grouping
composed of the Th1 cytokine IFN-c and the innate cytokine IL-6.
Correlating the extracted PCs from the factor analysis with
CHI3L1 while controlling for sex, age group, infection area, and
infection status revealed a negative association between PC2 and
CHI3L1 levels (r =20.184, p= 0.037). All other PCs showed no
significant correlation with CHI3L1 levels PC1 (r =20.006,
p = 0.934), PC3 (r = 0.028, p= 0.755), and PC4 (r =20.112,
p = 0.206).
Discussion
Infection with schistosome parasites causes a host inflammatory
response responsible for much of the disease-associated pathology
Figure 1. Age profiles for infection intensity and CHI3L1 serum protein levels. Age profiles for the study areas, shown as circles for the high
infection area and squares for the low infection areas. Bars represent standard error of the mean. A. Infection intensity exhibiting a peak shift between
the two villages. B. Chitinase 3-like 1 protein showing no peak shift between the two villages.
doi:10.1371/journal.pntd.0001898.g001
Table 2. F and P values of the factors affecting levels of
chitinase 3-like 1 in serum.
Variable df F p value
Sex 1 2.867 0.091
Residential Area 1 69.585** #0.000
Age Group 5 25.909** #0.000
Infection Status 1 3.552 0.060
Infection Status * Age Group 5 3.017** 0.010
Residential Area * Age Group 5 1.653 0.143
Infection Status * Residential Area 1 1.916 0.167
Note. F and P values from analysis of variance (total degrees of freedom
(df) = 858). Sex: Male or Female; Residential areas: high infection area and low
infection area; Age groups as described in Table 1; Infection status: egg positive
or egg negative.
**Indicates significant p values.
doi:10.1371/journal.pntd.0001898.t002
Figure 2. Relationship between CHI3L1 protein and infection
status in different age groups. Figure shows mean levels of CHI3L1
protein (log10(x+1)). Uninfected individuals (open) compared to
infected (solid). Bars represent standard error of the mean. P-values
are obtained from posthoc tests after taking into account residential
area. Significant p-values are indicated in bold.
doi:10.1371/journal.pntd.0001898.g002
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[3,4,5]. As CHI3L1 has been associated with numerous other
inflammatory and type-2 diseases we investigated the relationship
between CHI3L1 levels and schistosome infection in a population
naturally exposed to S. haematobium [19,20,21].
Our study presents the first comparative analysis of CHI3L1
levels in human populations who are of the same ethnicity and
socioeconomic status but differing helminth endemicity. Similar to
reports from non-schistosome endemic areas, CHI3L1 showed a
significant increase in levels with increasing age [35], a pattern
reported to be due to an increasing level of background
inflammation associated with ageing and the onset of age-related
diseases [35,36]. In this study we demonstrated that overall levels
of CHI3L1 are higher in the HIA compared to the LIA across all
age groups. As the populations are similar in ethnicity and in
exposure to other common infections such as Plasmodium, the only
differing characteristic being exposure to schistosome infection
[37], this result suggests that the difference in schistosome infection
may contribute to differences in CHI3L1 levels and is supported
by the observation that schistosome infected people had higher
levels of CHI3L1 than uninfected people, independent of
residential area. Furthermore CHI3L1 levels were reduced
following elimination of adult worms from the body via curative
antihelminthic treatment [38], determined via egg count and the
disappearance of visible haematuria. Taken together these
observations suggest that CHI3L1 levels are related to current
levels of infection. The significant interaction between age and
infection status with the difference between schistosome-infected
and uninfected people being the most apparent in the youngest
age group is consistent with a dynamic relationship between
infection status and CHI3L1 levels as people age. Other factors
confounding the relationship between CHI3L1 and infection
status pre- and post- antihelminthic treatment, such as the onset of
age-related diseases [35] requires further investigation.
A previous study of schistosome related pathology has suggested
that it is infection status rather than infection intensity that is
related to pathology [12]. Our results are consistent with this
observation in that it was infection status rather than intensity that
was associated with CHI3L1 levels. Accordingly, the change in
CHI3L1 on clearing infection was not related to pre-treatment
infection intensity (data not shown).
To determine if CHI3L1 levels differ in people with visible signs
of pathology, we compared levels of the protein in children who
had visible haematuria to age and infection intensity matched
controls confirmed negative for haematuria. We showed that
within infected children, CHI3L1 levels were higher in haematuria
positive compared to haematuria negative individuals, suggesting
that elevated CHI3L1 levels are associated with infection and
morbidity in S. haematobium infection. Further studies expanding on
the numbers of individuals assessed for haematuria and CHI3L1
levels will be required to confirm this association.
The inflammatory immune response associated with schistoso-
miasis infection is modulated by adult schistosome worms as well
as by the egg antigens [39]. Treatment with PZQ kills the adult
schistosome worms and removes their recently laid eggs [40],
eliminating the source of inflammation. The decrease in CHI3L1
levels in the treated group may therefore be related to a reduction
in inflammatory processes associated with schistosome infection
and egg laying, and support previous studies in liver disease that
suggests CHI3L1 levels are a bio-indicator of early phases of
fibrogenesis [21]. However, while CHI3L1 is associated with
inflammation, as yet, its precise function remains unknown. In
mice, for instance, inflammatory signals induced by LPS and IFN-
c can both stimulate and inhibit chitinase like protein (CLP)
expression in a context dependent manner [41]. As the function of
these CLPs is elucidated, it may be possible to make a more
educated assessment as to why CHI3L1 is downregulated on
clearance of schistosome adult worms.
To determine if elevated CHI3L1 levels are a marker of
schistosome-related immunopathology, further studies with larger
numbers of people with defined levels of pathology (assessed using
current standard markers of schistosome- related immunopathol-
ogy such as ultrasonography) are necessary. Furthermore, in order
to resolve the mechanism behind the observed elevation as well as
the relationship between CHI3L1 levels and infection status in the
different age groups mechanistic studies on both human and
mouse models will be required. One possible explanation is that
this could be due to differences in the stage of the pathological
processes that the hosts were experiencing, with the younger
individuals being at a stage of disease where lesion repair and
granuloma formation is actively occurring [7,9]. Given the lack of
significant difference in CHI3L1 levels in infected vs. uninfected
individuals in the older age groups, it is unsurprising that treating
these individuals does not result in a significant reduction in their
CHI3L1 levels. Older individuals have had a lifetime of exposure
to infection, and may be experiencing more advanced pathology
associated with inactive disease including bladder calcification and
Figure 3. CHI3L1 levels in haematuria positive and haematuria
negative individuals. CHI3L1 levels according to haematuria status. P
values are obtained from t-test on age, sex and infection status
matched individuals.
doi:10.1371/journal.pntd.0001898.g003
Figure 4. Effect of treatment on CHI3L1 protein levels. Mean
CHI3L1 expression within an untreated (n = 136) and a treated
population (n = 110) by age group. Week 0 (open), 6 weeks later (solid),
bars represent standard error of the mean. Significant p-values from
posthoc ANOVA are indicated in bold.
doi:10.1371/journal.pntd.0001898.g004
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a drop in egg excretion [7,9], as well as a higher background level
of CHI3L1 associated with age [35]. There were no macro-
haematuria cases observed post-treatment and this is consistent
with other studies reporting a reversal/clearance of pathology
[42]. These previous studies also reported that the groups
experiencing the greatest reduction in morbidity following PZQ
treatment are the younger age groups where infection levels are
rising but who are not yet suffering from irreversible schistosome
pathology [42].
In determining the systemic cytokine environment in the
participants relative to CHI3L1, we showed that levels of the
measured Th1 and Th2 cytokines were not associated with
CHI3L1 levels, perhaps due to the cytokines acting locally at sites
of infection [2], but there was an inverse association between
CHI3L1 and levels of IL-10 and IL-17A. IL-10 can dampen a
damaging pro-inflammatory response [43] and has previously
been associated with schistosome infection levels [44] where it can
limit pathology during infection as is suggested in the case of
bladder pathology [45]. IL-17A is primarily regarded as a pro-
inflammatory cytokine and has been found to be associated with
numerous inflammatory diseases [46]. Despite being reported to
have a role in the schistosome mediated pathological process in
murine studies [47], a previous study of people resident in the
same region showed less systemic IL-17A levels in S. haematobium
infected people compared to uninfected individuals [32], and here
we describe a negative association with CHI3L1 levels and
systemic IL-17A. The relevance and implications of our cytokine
findings for CHI3L1 levels in schistosome infection and for
schistosome-related pathology remains to be determined in
mechanistic studies.
Our study investigated CHI3L1 in a single infection setting; it
will be interesting to see if the same relationship with infection
status pre- and post- treatment is also observed in S. mansoni
infection where there is no existing marker for early morbidity
[10]. Indeed, in order to fully evaluate CHI3L1 as a potential
pathology marker the study must be extended to other settings,
including co-infections and differing ethnic populations, and the
results compared to existing and candidate pathological markers.
Overall, our study has demonstrated that CHI3L1 levels are
associated with schistosome infection status regardless of cumula-
tive history of exposure to infection. Moreover, CHI3L1 is higher
in people showing clinical signs of urogenital schistosomiasis
(haematuria) compared to infected people presenting no haema-
turia. Antihelminthic treatment results in a significant reduction of
CHI3L1 levels coinciding with the removal of adult schistosome
worms. Both before and after curative treatment the difference in
CHI3L1 between infected and uninfected people is greatest in the
youngest age group where infection levels are rising rapidly,
indicating not only a potential mechanism for schistosomiasis
associated pathological processes, but also of an early onset of
these pathological processes. The associations between CHI3L1
and schistosome infection warrants further investigation to
determine the utility of CHI3L1 as a diagnostic marker for
schistosome related morbidity as well as a tool for evaluating the
impact of S. haematobium control programmes.
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